Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Net Income of -$7.73 million for fiscal year 2024.
CERO THERAPEUTICS HOLDINGS, INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Net Income | -$572.2K +92.2% |
-$7.29M -991.7% |
-$667.7K | — |
| Diluted EPS | -$97.90 +92.2% |
-$1248.64 | — | — |
| Total Assets | $6.21M +21.1% |
$5.13M -87.9% |
$42.37M -76.5% |
$180.08M |
| Cash and Equivalents | — | $96.9K -79.6% |
$475.9K | $0.00 |
| Stockholders Equity | -$1.89M +95.5% |
-$42.06M -282.3% |
-$11.00M | $0.00 |
| R&D Expense | $764.2K -85.6% |
$5.29M | — | — |
| Operating Income | -$897.1K +88.3% |
-$7.68M -164.2% |
-$2.91M | — |
| Shares Outstanding | — | 5,845 | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.86M | -14.9% | +10.4% |
| Diluted EPS | September 30, 2025 | -$9.10 | +94.7% | +85.3% |
| Total Assets | September 30, 2025 | $3.91M | — | -36.9% |
| Cash and Equivalents | September 30, 2025 | $1.90M | — | -40.6% |
| Stockholders Equity | September 30, 2025 | -$4.54M | — | -178.1% |
| R&D Expense | September 30, 2025 | $2.39M | +34.5% | -13.4% |
| Operating Income | September 30, 2025 | -$4.36M | +0.9% | +7.6% |
| Shares Outstanding | December 31, 2023 | 9.07M | — | — |
- CERO THERAPEUTICS HOLDINGS, INC. reported Net Income of -$7.73 million for fiscal year 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed a decrease of -1251.3% in Net Income compared to the prior fiscal year.
- CERO THERAPEUTICS HOLDINGS, INC. reported Diluted EPS of $18.15 per share (loss) for fiscal year 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +81.5% in Diluted EPS compared to the prior fiscal year.
- CERO THERAPEUTICS HOLDINGS, INC. reported Total Assets of $6.21 million for fiscal year 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +21.1% in Total Assets compared to the prior fiscal year.
- CERO THERAPEUTICS HOLDINGS, INC. reported Cash and Equivalents of $96.9 thousand for fiscal year 2023.
- CERO THERAPEUTICS HOLDINGS, INC. showed a decrease of -79.6% in Cash and Equivalents compared to the prior fiscal year.
- CERO THERAPEUTICS HOLDINGS, INC. reported Stockholders Equity of -$1.89 million for fiscal year 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +95.5% in Stockholders Equity compared to the prior fiscal year.
- CERO THERAPEUTICS HOLDINGS, INC. reported R&D Expense of $6.32 million for fiscal year 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed an increase of +726.4% in R&D Expense compared to the prior fiscal year.
- CERO THERAPEUTICS HOLDINGS, INC. reported Operating Income of -$15.30 million for fiscal year 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed a decrease of -1605.5% in Operating Income compared to the prior fiscal year.
- CERO THERAPEUTICS HOLDINGS, INC. reported Shares Outstanding of 5.8 thousand shares for fiscal year 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: